Company Overview and News
The brick-and-mortar carnage, led by Amazon (AMZN), which is selling products at razor-thin margins, sent the shares of Bed Bath & Beyond (BBBY) and other offline retailers onto a downward trajectory. Trading at $80 per share at the end of 2013, we are now looking at a price of less than $20. But make no mistake, it is not only AMZN’s aggressive business model that sent the shares tumbling. Management of BBBY misbehaved in fiscal 2014, funding excessive share repurchases with debt while selling significant amounts of their own stock.
LOW HD GME BBBY
Bed Bath & Beyond (BBBY - Free Report) is expected to deliver a year-over-year decline in earnings on higher revenues when it reports results for the quarter ended August 2018. This widely-known consensus outlook gives a good sense of the company's earnings picture, but how the actual results compare to these estimates is a powerful factor that could impact its near-term stock price.
Bed Bath & Beyond Inc. (BBBY - Free Report) was a big mover last session, as the company saw its shares rise nearly 6% on the day. The move came on solid volume too with far more shares changing hands than in a normal session. This breaks the recent trend of the company, as the stock is now trading above the volatile price range of $17.53 to $18.96 in the past one-month time frame.
MDPEB MDP FIVE BBBY
Stocks were indicated to open marginally lower after news that President Trump is set to enact more tariffs against China. U.S. equity indexes remain very close to all-time highs, while most international markets are not close to theirs. One issue that must be considered is that investors have seen less upside from buying on market pullbacks than in prior years. Investors also need to be considering how they want to have their investments positioned for the rest of 2018.
ATHTF COST AXP ANTM V TWTR KHC TRI CI PLAY ARMK ADS BBBY ANTX
I have been on quite the buying spree lately and have made 7 investment purchases within a 4-week window that I'm excited to share with everyone. The stock purchases may be within a company that was already in my dividend portfolio or this could be an entire new position. The one common trait that they all share is fairly simple - the stock purchases all produce growing dividends and pay on a quarterly basis!
CZNC ITW NWFL BBBY
2018-09-10 zacks - 1
Bed Bath & Beyond Inc. (BBBY - Free Report) is failing to impress investors due to multiple headwinds like soft comparable-store sales (comps) and margin pressures, among others. Though the company has impressive earnings and sales surprise history, along with solid store-growth endeavors, these are not reflected in its share price performance. Shares of this Zacks Rank #4 (Sell) have lost 34.4% in the past year against the industry’s 21% rally.
ZUMZ URBN FIVE BBBY
Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn’t want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing discounts when compared to fair value? One way to find these companies is by looking at several key metrics and financial ratios, many of which are crucial in the value stock selection process.
August has been hot and heavy with dividend stock purchases already! As you can tell from the title of the article, this isn't about just one dividend stock purchase. We are talking a nice double triple punch to the portfolio. However, "punch" has a much more positive tone. Prices were ripe, and I deployed a bit of capital into three young dividend-producing and growing stocks!
ITW WRK BBBY
Getting to the mid-point of summer and it's time to warm up my dividend stock watch list article. Time for me to put the pencil to paper, analyze dividend stocks that may or may not be undervalued and ripe for my portfolio. I am looking forward to deploy capital that I managed to save over the last 4+ weeks, in order to add dividend income to my forward-looking projection and reduce the time needed to being financial independent! Are you ready to grab that ice-cold… drink and check out my dividend stock watch list for August? Keep on reading then!
ITW WRK BBBY
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
Silicon Investor Message Boards
This table lists all message boards related to BBBY / Bed Bath & Beyond Inc. on message board site Silicon Investor.
|Bed, Bath, and Beyond (BBBY)||Bed, Bath, and Beyond (BBBY)||Bed, Bath, and Beyond (BBBY)||ABB and ABB ADRu0027s (ABBBY)||ABB and ABB ADRu0027s (ABBBY)||ABB and ABB ADRu0027s (ABBBY)|
as of ET